How comparable are ecnoglutide and retatrutide on the evidence available?

Conditions: ecnoglutide · retatrutide.

I would like the axes of comparison first and the recommendation second.

I have tried the first option and it works; the question is whether the second is better rather than merely different.

What is the actual trade-off, and does it matter at the scale I am working at?

Answer first: read the primary endpoint, the comparator and the population before you read the effect size. Almost every argument on this site about a trial is really an argument about one of those three.

Non-inferiority and superiority designs are not interchangeable. A non-inferiority result says the new agent is not meaningfully worse against a pre-specified margin — it does not say it is as good, and it certainly does not say it is better.

Intention-to-treat and per-protocol analyses answer different questions. ITT asks what happens if you offer the treatment; per-protocol asks what happens if it is taken as directed. The gap between the two is a measure of how tolerable the protocol was.

One qualification: absence of a signal in a trial of this size is not evidence of absence for a rare event. It is evidence that the event is rarer than the trial could detect.

Read the protocol and the statistical analysis plan if the result matters to you. Both are usually published alongside.

edited 16 Apr 2026 by jo_vandeberg — added the method parameters

Look at the discontinuation rate alongside the efficacy figure. A large effect in the two thirds who stayed is a different result from a large effect in everyone.

Placebo arms in this class are not nothing. Lifestyle-intervention placebo arms in the major obesity trials commonly lose two to three per cent of body weight, so an active-arm figure quoted without its comparator overstates the drug effect by roughly that much.

Confidence intervals matter more than point estimates when two trials disagree. Two studies reporting fifteen and twenty per cent whose intervals overlap heavily have not disagreed about anything.

Quote the interval alongside the estimate and half the disagreements on this site would not start.

Worth being precise here: this is answerable from the published record, but only if you take the placebo arm seriously rather than reading the active arm alone.

Open-label extensions are not the same evidence as the randomised phase. Once everyone knows what they are taking, the reported outcomes acquire a bias that no analysis fully removes.

If a claim cannot be traced to a named trial with a named endpoint, treat it as a claim rather than as evidence.

The short version: the effect is real, the magnitude depends on the population, and the population is usually the part that gets dropped when a result is quoted second-hand.

Trial populations are selected. Exclusion criteria in this class routinely remove people with significant renal impairment, prior pancreatitis and unstable psychiatric illness, which is exactly the population the results are then quoted for.

Meta-analyses in this area are dominated by whichever trial contributed the most participants, so read the forest plot rather than the summary estimate.

When two sources disagree, the answer is almost always in the methods section of the one you have not read.